Wave faces key test in bid to challenge Sarepta in DMD

Wave faces key test in bid to challenge Sarepta in DMD

Source: 
Biopharma Dive
snippet: 

Forthcoming trial results will show whether Wave's experimental drug can compete with Sarepta's Exondys 51 in Duchenne muscular dystrophy.